| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target is reactive oxygen species (ROS) and free radicals. Antioxidant agent-1 acts as a free radical scavenger, neutralizing harmful reactive species such as superoxide anion (O2-), hydroxyl radical (OH•), and DPPH radicals. It may also interact with lipid peroxidation chain reactions, protecting cellular membranes from oxidative damage.
|
|---|---|
| ln Vitro |
In vitro, Antioxidant agent-1 shows potent antioxidant activity in chemical scavenging assays. It effectively scavenges DPPH, ABTS, and superoxide radicals in a concentration-dependent manner, with a typical IC50 in the low micromolar range. Its activity is attributed to its chalcone scaffold, which contains conjugated double bonds and phenolic hydroxyl groups that stabilize free radicals.
|
| ln Vivo |
Specific in vivo activity data for this compound is not publicly available. Based on its antioxidant mechanism, it could be tested in animal models of oxidative stress, such as ischemia-reperfusion injury, neuroinflammation, or drug-induced hepatotoxicity, to assess its potential to reduce markers of oxidative damage (e.g., malondialdehyde, protein carbonylation) and improve survival or organ function.
|
| Enzyme Assay |
A DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging assay is performed. A solution of DPPH in methanol (typically 0.1 mM, purple color) is prepared. Varying concentrations of Antioxidant agent-1 (0-200 uM) are added and incubated in the dark for 30 minutes at room temperature. The decrease in absorbance at 517 nm is measured spectrophotometrically, and the percentage of scavenging activity is calculated relative to control (no compound). ABTS and FRAP assays can also be used.
|
| Cell Assay |
Antioxidant agent-1 is tested in cell-based oxidative stress models. Cultured cells (e.g., HepG2, PC12, or primary neurons) are pre-incubated with the compound (0-100 uM) for 1-2 hours, then exposed to an oxidative stress-inducing agent such as hydrogen peroxide (H2O2, 0.5-1 mM) or paraquat. After 4-24 hours, cell viability is measured by MTT or LDH release assay. The compound‘s ability to prevent cell death and reduce intracellular ROS levels (measured by DCFH-DA fluorescence) is quantified.
|
| Animal Protocol |
An in vivo protocol may involve a mouse model of acetaminophen (APAP)-induced hepatotoxicity. C57BL/6 mice are fasted overnight, then treated with APAP (300 mg/kg, i.p.) to induce acute liver injury. Antioxidant agent-1 (10-50 mg/kg) is administered intraperitoneally or orally 1 hour before or after APAP challenge. After 6-24 hours, blood is collected for serum ALT/AST measurement, and liver tissue is harvested for H&E histology and measurement of malondialdehyde (MDA) and glutathione (GSH) levels.
|
| ADME/Pharmacokinetics |
Detailed PK data for Antioxidant agent-1 is not available. As a small chalcone derivative with a molecular weight of 240.25 (C15H12O3), it is expected to have moderate lipophilicity (LogP predicted ~2.5-3.0). It is soluble in DMSO (25 mg/mL) and has good solubility in organic solvents. Oral bioavailability and plasma half-life would need to be determined experimentally.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Antioxidant agent-1 has not been published. As a naturally occurring chalcone-like compound, it is expected to have low acute toxicity. In vitro, it shows no significant cytotoxicity at concentrations up to 100 uM in most normal cell lines. It is for research use only and has not undergone formal toxicological evaluation for human use.
|
| References |
[1]. Okolo EN, et al. New chalcone derivatives as potential antimicrobial and antioxidant agent. Sci Rep. 2021 Nov 5;11(1):21781.
|
| Additional Infomation |
Antioxidant agent-1 is also known as (E)-3-(3,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one. It is a new chalcone derivative with potential antimicrobial and antioxidant activities (references include Okolo EN, et al. Sci Rep. 2021). It is a research-grade compound and has no approved therapeutic indications or clinical trial status.
|
| Molecular Formula |
C15H12O3
|
|---|---|
| Molecular Weight |
240.25
|
| Exact Mass |
240.079
|
| CAS # |
136068-43-4
|
| PubChem CID |
6474896
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.993
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=CC=CC=C1)(=O)/C=C/C1=CC=C(O)C(O)=C1
|
| InChi Key |
HHKVOYUYPYZFHJ-SOFGYWHQSA-N
|
| InChi Code |
InChI=1S/C15H12O3/c16-13(12-4-2-1-3-5-12)8-6-11-7-9-14(17)15(18)10-11/h1-10,17-18H/b8-6+
|
| Chemical Name |
(E)-3-(3,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (104.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1623 mL | 20.8117 mL | 41.6233 mL | |
| 5 mM | 0.8325 mL | 4.1623 mL | 8.3247 mL | |
| 10 mM | 0.4162 mL | 2.0812 mL | 4.1623 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
